الرئيسي FierceBiotech ٢٠ أبريل ٢٠٢٦ Agenus focuses on survival data as 0% response rate triggers primary miss Agenus focuses on survival data as 0% response rate triggers primary miss فتح إشارات ذات صلة FierceBiotech ٢٠ أبريل ٢٠٢٦ Odyssey charts fresh voyage to public markets after abandoning IPO plans last year FierceBiotech ٢٠ أبريل ٢٠٢٦ AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win FierceBiotech ٢٠ أبريل ٢٠٢٦ How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients